ConforMIS Inc (CFMS) Receives Average Recommendation of “Buy” from Brokerages

Share on StockTwits

ConforMIS Inc (NASDAQ:CFMS) has earned an average rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $2.88.

CFMS has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of ConforMIS from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 13th. Oppenheimer set a $3.00 price target on shares of ConforMIS and gave the company a “buy” rating in a report on Friday, December 14th. Finally, ValuEngine raised shares of ConforMIS from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.

CFMS stock traded up $0.02 during trading on Thursday, reaching $2.72. 1,147,351 shares of the company were exchanged, compared to its average volume of 1,110,763. The company has a market cap of $184.74 million, a P/E ratio of -3.68 and a beta of 2.92. ConforMIS has a 52-week low of $0.36 and a 52-week high of $2.95. The company has a current ratio of 4.22, a quick ratio of 3.38 and a debt-to-equity ratio of 0.41.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings data on Wednesday, February 6th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $22.05 million for the quarter, compared to the consensus estimate of $21.45 million. ConforMIS had a negative net margin of 48.30% and a negative return on equity of 91.73%. On average, equities research analysts expect that ConforMIS will post -0.43 earnings per share for the current year.

In other ConforMIS news, major shareholder Archon Capital Management Llc purchased 560,000 shares of ConforMIS stock in a transaction on Wednesday, January 2nd. The shares were bought at an average price of $0.41 per share, with a total value of $229,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.38% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in CFMS. Gabelli Funds LLC raised its position in shares of ConforMIS by 76.2% in the fourth quarter. Gabelli Funds LLC now owns 104,056 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 45,000 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of ConforMIS by 26.0% in the fourth quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 26,202 shares during the last quarter. Sio Capital Management LLC raised its position in shares of ConforMIS by 13.2% in the third quarter. Sio Capital Management LLC now owns 1,861,789 shares of the medical instruments supplier’s stock valued at $1,973,000 after buying an additional 217,275 shares during the last quarter. Vanguard Group Inc raised its position in shares of ConforMIS by 1.3% in the third quarter. Vanguard Group Inc now owns 2,230,254 shares of the medical instruments supplier’s stock valued at $2,364,000 after buying an additional 28,556 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of ConforMIS by 10.0% in the third quarter. Renaissance Technologies LLC now owns 3,306,461 shares of the medical instruments supplier’s stock valued at $3,505,000 after buying an additional 299,561 shares during the last quarter. 29.61% of the stock is currently owned by institutional investors.

About ConforMIS

Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Featured Story: Put Option Volume

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.